medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 5

<< Back Next >>

Ann Hepatol 2017; 16 (5)

Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma

Brahmania M, Ahmed O, Kelley M, Kowgier M, Khalili K, Beecroft R, Renner EL, Wong D, Shah H, Feld J, Janssen HLA, Sherman M

Language: English
References: 13
Page: 765-771
PDF size: 183.41 Kb.


ABSTRACT

Introduction. Radiofrequency ablation (RFA) is a recommended curative intent treatment option for patients with early stage hepatocellular carcinoma (HCC). We investigated if wait times for RFA were associated with residual tumor, tumor recurrence, need for liver transplantation, or death. Material and methods. We conducted a retrospective study of patients diagnosed with HCC between January 2010 and December 2013 presenting to University Health Network (UHN) in Toronto, Canada. All patients receiving curative intent RFA for HCC were included. Multivariable Cox regression was used to determine if wait times were associated with clinical outcomes. Results. 219 patients were included in the study. 72.6% were male and the median age was 62.7 years (IQR 55.6-71). Median tumor size at diagnosis was 21.5 mm (IQR 17-26); median MELD was 8.7 (IQR 7.2-11.4) and 57.1% were Barcelona stage 0. The cause of liver disease was viral hepatitis in 73.5% (Hepatitis B and C). The median time from HCC diagnosis to RFA treatment was 96 days (IQR 75-139). In multivariate analysis, wait time was not associated with requiring liver transplant or tumor recurrence, however, each incremental 30-day wait time was associated with an increased risk of residual tumor (HR = 1.09; 95% CI 1.01-1.19; p = 0.033) as well as death (HR = 1.23; 95% CI 1.11-1.36; p ≤ 0.001). Conclusion. Incremental 30-day wait times are associated with a 9% increased risk of residual tumor and a 23% increased risk of death. We have identified system gaps where quality improvement measures can be implemented to reduce wait times and allocate resources for future RFA treatment, which may improve both quality and efficiency of HCC care.


REFERENCES

  1. El-Serag HB. Hepatocellular carcinoma. New Engl J Med 2011; 365: 1118-27.

  2. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The Oncologist 2010; 15: 5-13.

  3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.

  4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J Med 1996; 334: 693-9.

  5. European Association for Study of Liver; European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Can 2012; 48: 599-64.

  6. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63.

  7. Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Roberts JP, et al. Excellent Outcome Following Down-Staging of Hepatocellular Carcinoma Prior to Liver Transplantation: An Intention-to-Treat Analysis. Hepatology 2008; 48: 819-27.

  8. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Xiao JL, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery 2006; 243: 321-8.

  9. Livraghi T, Meloni F, Stasi M Di, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47: 82-9.

  10. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in Advanced Hepatocellular Carcinoma. New Engl J Med 2008; 359: 378-90.

  11. Available from: https://www.cancercare.on.ca/cms/One. aspx?portalId=1377&pageId=8844. Last accessed March 15, 2017.

  12. Baldassarre FG, Baerlocher M, Beecroft R, Dawson L. Focal Tumour ablation: thermal ablation of hepatocellular carcinoma and metastases from colorectal carcinoma: evidence summary [Internet]. Cancer Care Ontario; 2014 Jul [cited 2014 Jul 28]. Available from: https://www.cancercare.on.ca/.

  13. Khalili K, Menezes R, Kim TK, Yazdi LK, Jang HJ, Sharma S, Feld J, et al. The effectiveness of ultrasound surveillance for hepatocellular carcinoma in a Canadian centre and determinants of its success. Canad J Gastroenterol Hepatol 2015; 29: 267-73.




2020     |     www.medigraphic.com